Announcement Summary

Entity name

CRESO PHARMA LIMITED

Announcement Type

New announcement

Date of this announcement

25/10/2021

The Proposed issue is:

Total number of +securities proposed to be issued for a placement or other type of issue

ASX +security code	+Security description	Maximum Number of +securities to be issued
New class-code to be confirmed	Performance Shares	6,000,000

Proposed +issue date

10/12/2021

Refer to next page for full details of the announcement

Part 1 - Entity and announcement details

1.1 Name of +Entity

CRESO PHARMA LIMITED

We (the entity named above) give ASX the following information about a proposed issue of +securities and, if ASX agrees to +quote any of the +securities (including any rights) on a +deferred settlement basis, we agree to the matters set out in Appendix 3B of the ASX Listing Rules.

If the +securities are being offered under a +disclosure document or +PDS and are intended to be quoted on ASX, we also apply for quotation of all of the +securities that may be issued under the +disclosure document or +PDS on the terms set out in Appendix 2A of the ASX Listing Rules (on the understanding that once the final number of +securities issued under the +disclosure document or +PDS is known, in accordance with Listing Rule 3.10.3C, we will complete and lodge with ASX an Appendix 2A online form notifying ASX of their issue and applying for their quotation).

1.2 Registered Number Type

Registration Number

ABN

89609406911

1.3 ASX issuer code

CPH

1.4 The announcement is

☑ New announcement

1.5 Date of this announcement

25/10/2021

1.6 The Proposed issue is:

A placement or other type of issue

Part 7 - Details of proposed placement or other issue

Part 7A - Conditions

7A.1 Do any external approvals need to be obtained or other conditions satisfied before the placement or other type of issue can proceed on an unconditional basis? Yes

7A.1a Conditions

Approval/Condition Is the date estimated or ** Approval Date for determination actual? received/condition met? +Security holder approval 8/12/2021 No

Comments

Subject to ASX and shareholder approval, the Company intends to issue 6 million performance shares to the vendors of the assets of ImpACTIVE Holdings Ltd, with 3 million Performance Shares converting into Creso Shares upon reaching 20 million dollars in audited gross sales revenue of ImpACTIVE products in 36 months, and another 3 million of Performance Shares converting into Creso Shares upon reaching 40 million dollars in audited gross sales revenue of ImpACTIVE products within 60 months. For further information refer to ASX Release dated 25 October 2021.

Part 7B - Issue details

Is the proposed security a 'New class' (+securities in a class that is not yet quoted or recorded by ASX) or an 'Existing class' (additional securities in a class that is already quoted or recorded by ASX)? New class

Will the proposed issue of this +security include an offer of attaching +securities? ☑ No

Details of +securities proposed to be issued

ISIN Code (if Issuer is a foreign company and +securities are non CDIs)

Have you received confirmation from Will the entity be seeking quotation ASX that the terms of the proposed +securities are appropriate and equitable under listing rule 6.1? ☑ No

of the 'new' class of +securities on ASX? ☑ No

Proposed issue of securities

ASX +security code +Security description

New class-code to be confirmed Performance Shares

+Security type

Performance shares/units

Number of +securities proposed to be issued

6,000,000

Offer price details

Are the +securities proposed to be issued being issued for a cash consideration?
⊗ No

Please describe the consideration being provided for the +securities

Subject to ASX and shareholder approval, the Company intends to issue 6,000,000 Performance Shares to the vendors of the assets of ImpACTIVE Holdings Ltd. For further information, refer to the ASX release dated 25 October 2021.

Please provide an estimate of the AUD equivalent of the consideration being provided for the +securities

Will all the +securities issued in this class rank equally in all respects from their issue date?

Yes

Performance shares/units details

+Security currency

AUD - Australian Dollar

Will there be CDIs issued over the +securities?

No

Is it a partly paid class of +security?

☑ No

Is it a stapled +security?

☑ No

Please provide a URL link for a document lodged with ASX setting out the material terms of the +securities proposed to be issued or provide the information by separate announcement.

For further information, refer to the ASX release dated 25 October 2021.

Part 7C - Timetable

7C.1 Proposed +issue date

10/12/2021

Part 7D - Listing Rule requirements

7D.1 Has the entity obtained, or is it obtaining, +security holder approval for the entire issue under listing rule 7.1?
✓ Yes

7D.1a Date of meeting or proposed meeting to approve the issue under listing rule 7.1

7D.2 Is a party referred to in listing rule 10.11 participating in the proposed issue? $\ensuremath{\mathfrak{S}}$ No

7D.3 Will any of the +securities to be issued be +restricted securities for the purposes of the listing rules?

© No

7D.4 Will any of the +securities to be issued be subject to +voluntary escrow? $\ensuremath{\mathfrak{S}}$ No

Part 7E - Fees and expenses

7E.1 Will there be a lead manager or broker to the proposed issue?

⊗ No

7E.4 Details of any other material fees or costs to be incurred by the entity in connection with the proposed issue

None directly incurred in connection with the proposed issues, however the Company incurred costs in relation to the acquisition of the assets of ImpACTIVE Holdings Ltd.

Part 7F - Further Information

7F.01 The purpose(s) for which the entity is issuing the securities

Deferred consideration based on revenue milestones for the acquisition of the assets of ImpACTIVE Holdings Ltd.

7F.1 Will the entity be changing its dividend/distribution policy if the proposed issue proceeds? $\ensuremath{\mathfrak{G}}$ No

7F.2 Any other information the entity wishes to provide about the proposed issue

The issue date set out in this Appendix 3B is indicative and depends on when the proposed General Meeting of shareholders is held. Refer to the ASX announcement released on 25 October 2021.